Amalgamated Financial’s Cogent Biosciences COGT Stock Holding History

Amalgamated Financial’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$37K	Buy	+4,942	New	+$34.4K	﹤0.01%	2544

Other funds holding COGT

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Janus Henderson Group

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Amalgamated Financial's COGT Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Cogent Biosciences (COGT) in Q1 2022: 4,942 shares worth $37K. The stake represents ﹤0.01% of the portfolio and ranks #2544 among its holdings.

87 funds tracked by Wall St. Rank hold COGT as of Q1 2022.

Amalgamated Financial held 4,942 shares of Cogent Biosciences worth $37K as of Q1 2022.
Cogent Biosciences was a new Amalgamated Financial position in Q1 2022.
Cogent Biosciences made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2544 holding.
87 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.